{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:08:17Z","timestamp":1770433697918,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":6409,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1989,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ten children with Langerhans cell histiocytosis (histiocytosis X) either resistant to or intolerant of corticosteroids received etoposide (VP16). Nine responded. In one instance, partial diabetes insipidus was temporarily reversed. There was no major toxicity. Etoposide should be seriously considered as therapy for patients with LCH in whom the toxicity\/benefit ratio of steroid therapy is unacceptably high.<\/jats:p>","DOI":"10.1002\/mpo.2950170205","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T17:44:31Z","timestamp":1171993471000},"page":"97-100","source":"Crossref","is-referenced-by-count":57,"title":["Etoposide (VP16) in the treatment of multisystem langerhans cell histiocytosis (histiocytosis X)"],"prefix":"10.1002","volume":"17","author":[{"given":"V.","family":"Broadbent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Yeomans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"208","article-title":"Histiocytosis syndromes in children","volume":"8526","author":"Chu A","year":"1987","journal-title":"Lancet"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.60.7.605"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(75)80576-2"},{"key":"e_1_2_1_5_2","unstructured":"CeciA(for theAIEOP Group):Prospective cooperative trial AIEOP\u2010HX83 in childhood (15 years): Langerhans cell histiocytosis (Abstract). Histiocyte Society Meeting Bethesda 1987. Med Ped Onc (in press)."},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800515)45:10<2516::AID-CNCR2820451008>3.0.CO;2-V"},{"key":"e_1_2_1_7_2","first-page":"1","article-title":"Etoposide in the treatment of acute leukaemia in adults","volume":"9","author":"Varini M","year":"1982","journal-title":"Cancer Treat Rep (Suppl)"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860815)58:4<840::AID-CNCR2820580405>3.0.CO;2-Y"},{"key":"e_1_2_1_9_2","first-page":"238","article-title":"Etoposide in the treatment of multifocal eosinophilic granuloma","volume":"69","author":"Urbano\u2010Marquez A","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_10_2","first-page":"206","volume-title":"Histiocytosis X. Oxford text. med","author":"Pritchard J","year":"1987"},{"key":"e_1_2_1_11_2","volume-title":"Absolute oral bioavailability of etoposide (VP16) Proceedings Vepesid: Recent Advances and Future Prospects","author":"Smyth RD","year":"1985"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90127-2"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1986.tb00445.x"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","unstructured":"DungarD SecklJR GrantDB et al.:A short water deprivation test incorporating urinary argenine vasopressin estimation for the investigation of posterior pituitary function in children. Acta Endocrinol Jan1988 in press.","DOI":"10.1530\/acta.0.1170013"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1979.tb01637.x"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(75)80575-0"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950170205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950170205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T12:58:18Z","timestamp":1697979498000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950170205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989,1]]}},"alternative-id":["10.1002\/mpo.2950170205"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950170205","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,1]]}}}